Exelixis Q1 2025: Revenue $555.4M, GAAP EPS $0.55; raises FY2025 guidance by $100M

EXELIXIS, INC.

2025-Q1 EPS reported $0.55 revenue$555,447,000

Total revenues $555.4M (up 31% YoY); Cabozantinib U.S. net product revenues $513.3M (up 36% YoY).
GAAP diluted EPS $0.55 vs $0.12 in Q1 2024; Non-GAAP diluted EPS $0.62 vs $0.17.
Increasing 2025 full year net product revenues and total revenues guidance by $100M.
CABOMETYX launched in advanced NET after March FDA approval; initial reception positive.
Pipeline milestones: zanzalintinib pivotal readouts in CRC, nccRCC expected H2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.